New CBD & THC Cannabis Oils Now Shipping To Australia From Canada
New CBD & THC Cannabis Oils Now Shipping To Australia From Canada
MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) announced on Wednesday that Canadian-produced GMP Beacon Medical cannabis oil and inhalation cartridges have launched in the Australian medical marijuana market.
Medipharm Labs Corp.（多伦多证券交易所股票代码：LABS）（OTCQB: MEDIF）（FSE：MLZ）周三宣布，加拿大生产的GMP Beacon Medical大麻油和吸入药筒已在澳大利亚医用大麻市场上市。
The cannabis oil portfolio features a high CBD Isolate (THC-free) oil, a balanced oil and a THC dominant full spectrum oil made with Beacon's popular medical flower strains.
大麻油产品组合包括高CBD分离物（不含四氢大麻酚）油、平衡油和由Beacon广受欢迎的医用花卉菌株制成的四氢大麻酚占主导地位的全光谱油。
The inhalation cartridges include flavor-forward options popular with patients in the Canadian market and strain-specific full-spectrum cartridges that utilize flower varieties already favored by Beacon Medical patients.
吸入药筒包括在加拿大市场上深受患者欢迎的前瞻性口味选项，以及使用已经受到Beacon Medical患者青睐的花卉品种的菌株专用全光谱吸入药盒。
With Beacon Medical's Pink Kush and GSC products available in flower, oil and inhalation formats, the company provides physicians and patients with three delivery methods to consume the same full spectrum strains.
凭借Beacon Medical的Pink Kush和GSC产品以花、油和吸入形式提供，该公司为医生和患者提供了三种服用相同全谱菌株的给药方法。
Deliveries of inhalation cartridges to patients kicked off this week, and cannabis oils are scheduled to ship from Canada this week as well, the Toronto, Canada-based company said in a press release.
这家总部位于加拿大多伦多的公司在一份新闻稿中表示，本周开始向患者交付吸入药筒，大麻油也计划于本周从加拿大发货。
MediPharm holds an Australian GMP license from the Therapeutic Goods Administration (TGA), complemented by its GMP status from Health Canada (Drug Establishment License) and the US FDA.
MediPharm持有治疗用品管理局（TGA）颁发的澳大利亚GMP许可证，另外还拥有加拿大卫生部（药品机构许可证）和美国食品药品管理局颁发的GMP资格。
In July 2023, the TGA revised import and medical cannabis regulations, requiring all products to meet cGMP standards.
2023 年 7 月，TGA 修订了进口和医用大麻法规，要求所有产品都符合 cGMP 标准。
What's Next
下一步是什么
Beacon Medical Australia plans to educate and collect feedback on these products from physicians and patients with the help of its recently expanded medical scientific liaison field team.
Beacon Medical Australia计划在其最近扩大的医学科学联络现场小组的帮助下，对医生和患者进行教育和收集有关这些产品的反馈。
This allows MediPharm Labs further access to the Australian medical cannabis market.
这使Medipharm Labs能够进一步进入澳大利亚医用大麻市场。
Want to watch our Cannabis Capital Conference live? For existing subscribers you can get direct access through our research platform. For new users, you can get instant access here!
想现场观看我们的大麻资本会议吗？对于现有订阅者，您可以直接访问 通过我们的研究平台。对于新用户，你可以获得 点击此处即时访问！
MEDIF Price Action
MEDIF 价格行动
MediPharm's shares traded 0.2686% higher at $0.056 per share at the time of writing on Wednesday morning.
在周三上午撰写本文时，MediPharm的股价上涨0.2686％，至每股0.056美元。
Related News
相关新闻
- MediPharm Labs Breaks Free From Royalty Agreement, What It Means & What's Next
- Could Medical Cannabis Be The Answer For Fibromyalgia? Here's What New Study Found
- Cannabinoid-Focused Pharma Stock Slides On Q2 Earnings Report, Here Are The Details
- MediPharm Delivers Cannabis Clinical Trial Material To US Research Partner And Provides Update On FDA Status
- MediPharm Labs 打破了特许权使用费协议、这意味着什么以及下一步会发生什么
- 医用大麻能否成为纤维肌痛的答案？以下是新研究发现的内容
- 专注于大麻素的制药股在第二季度财报中下滑，以下是详细信息
- MediPharm向美国研究合作伙伴提供大麻临床试验材料，并提供有关FDA状态的最新信息
Photo: Courtesy of Kimzy Nanney on Unsplash
照片：由 Unsplash 上的 Kimzy Nanney 提供
译文内容由第三方软件翻译。